Figure 10.

TRIM24 siRNA effectively delivered by PSP Inhibition of bone loss in PC-3-PSMA+ bone metastasis model by PSP-mediated delivery of TRIM24 siRNA. (A). Tumor growth of various PC-3-PSMA+ groups treated as indicated was observed using BLI every week after the first treatment. (B). Bone loss of various PC-3-PSMA+ groups treated as indicated was observed using X-ray every two weeks after the first treatment. (C) Bone loss and (D) Bone volume analysis of various PC-3-PSMA+ groups treated as indicated was observed using micro-CT after the mice were anesthetized and sacrificed. Data are shown as the mean ± S.E. ns: not significant, *P<0.05, **P<0.01. Representative results of 3 independent experiments are shown.